Logo image of DMK

DMK PHARMACEUTICALS CORP (DMK) Stock Fundamental Analysis

NASDAQ:DMK - US00547W3079 - Common Stock

0.232 USD
+0 (+0.91%)
Last: 2/6/2024, 8:05:16 PM
0.1665 USD
-0.07 (-28.23%)
After Hours: 2/6/2024, 8:05:16 PM
Fundamental Rating

2

Taking everything into account, DMK scores 2 out of 10 in our fundamental rating. DMK was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of DMK have multiple concerns. While showing a medium growth rate, DMK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

DMK had negative earnings in the past year.
DMK had a negative operating cash flow in the past year.
DMK had negative earnings in each of the past 5 years.
DMK had a negative operating cash flow in each of the past 5 years.
DMK Yearly Net Income VS EBIT VS OCF VS FCFDMK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of DMK (-248.15%) is worse than 93.56% of its industry peers.
Industry RankSector Rank
ROA -248.15%
ROE N/A
ROIC N/A
ROA(3y)-173.97%
ROA(5y)-129.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMK Yearly ROA, ROE, ROICDMK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 1K -1K 2K 3K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DMK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMK Yearly Profit, Operating, Gross MarginsDMK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

More info and screens

1

2. Health

2.1 Basic Checks

DMK does not have a ROIC to compare to the WACC, probably because it is not profitable.
DMK has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for DMK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DMK Yearly Shares OutstandingDMK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M
DMK Yearly Total Debt VS Total AssetsDMK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

DMK has an Altman-Z score of -60.09. This is a bad value and indicates that DMK is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -60.09, DMK is doing worse than 94.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -60.09
ROIC/WACCN/A
WACC8.88%
DMK Yearly LT Debt VS Equity VS FCFDMK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

DMK has a Current Ratio of 0.58. This is a bad value and indicates that DMK is not financially healthy enough and could expect problems in meeting its short term obligations.
DMK has a Current ratio of 0.58. This is amonst the worse of the industry: DMK underperforms 92.57% of its industry peers.
DMK has a Quick Ratio of 0.58. This is a bad value and indicates that DMK is not financially healthy enough and could expect problems in meeting its short term obligations.
DMK has a Quick ratio of 0.54. This is amonst the worse of the industry: DMK underperforms 93.07% of its industry peers.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.54
DMK Yearly Current Assets VS Current LiabilitesDMK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.96% over the past year.
DMK shows a strong growth in Revenue. In the last year, the Revenue has grown by 160.36%.
DMK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.29% yearly.
EPS 1Y (TTM)37.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.73%
Revenue 1Y (TTM)160.36%
Revenue growth 3Y-40.07%
Revenue growth 5Y-18.29%
Sales Q2Q%-99.4%

3.2 Future

The Earnings Per Share is expected to grow by 25.25% on average over the next years. This is a very strong growth
Based on estimates for the next years, DMK will show a very strong growth in Revenue. The Revenue will grow by 53.75% on average per year.
EPS Next Y64.16%
EPS Next 2Y38.62%
EPS Next 3Y25.25%
EPS Next 5YN/A
Revenue Next Year-68.82%
Revenue Next 2Y-0.76%
Revenue Next 3Y53.75%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DMK Yearly Revenue VS EstimatesDMK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
DMK Yearly EPS VS EstimatesDMK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DMK. In the last year negative earnings were reported.
Also next year DMK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMK Price Earnings VS Forward Price EarningsDMK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMK Per share dataDMK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

DMK's earnings are expected to grow with 25.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y25.25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DMK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DMK PHARMACEUTICALS CORP

NASDAQ:DMK (2/6/2024, 8:05:16 PM)

After market: 0.1665 -0.07 (-28.23%)

0.232

+0 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)03-14 2024-03-14/bmo
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner Change0%
Market Cap2.34M
Analysts80
Price Target1.53 (559.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.17
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0.36
BVpS-0.49
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -248.15%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-173.97%
ROA(5y)-129.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.2%
Cap/Sales 2.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.54
Altman-Z -60.09
F-Score5
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)52.33%
Cap/Depr(5y)73.76%
Cap/Sales(3y)34.55%
Cap/Sales(5y)28.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.73%
EPS Next Y64.16%
EPS Next 2Y38.62%
EPS Next 3Y25.25%
EPS Next 5YN/A
Revenue 1Y (TTM)160.36%
Revenue growth 3Y-40.07%
Revenue growth 5Y-18.29%
Sales Q2Q%-99.4%
Revenue Next Year-68.82%
Revenue Next 2Y-0.76%
Revenue Next 3Y53.75%
Revenue Next 5YN/A
EBIT growth 1Y12.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y74.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.31%
OCF growth 3YN/A
OCF growth 5YN/A